Harold Burstein
Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (3)
Purpose: Circulating tumor cells (CTC) are biomarkers associated with poor prognosis and treatment resistance in hormone receptor–positive (HR+)/HER2-negative metastatic breast cancer (MBC). This analysis evaluates the prognostic role of baseline CTC enumeration and its interaction with treatment regimens in patients progressing on CDK4/6 inhibitors. Experimental Design: The PACE trial is a phase II, multicenter, randomized study of patients with HR+/HER2− MBC experiencing progression on aromatase inhibitors and CDK4/6 inhibitors. Patients were randomized 1:2:1 to receive fulvestrant (F), F + palbociclib (F + P), or F + P + avelumab (F + P + A). Baseline CTCs were enumerated using CellSearch with a threshold of ≥5 CTCs/7.5 mL to classify patients as stage IV indolent or stage IV aggressive . Concurrent ctDNA analysis was performed using Guardant360. Progression-free survival (PFS) was the primary endpoint. Results: Among 220 randomly assigned patients, 203 were evaluable for baseline CTCs; 76% had detectable CTCs and 49% were stage IV aggressive . Patients with de novo MBC were more frequently stage IV aggressive (47.5% vs. 30.8%). Baseline CTCs were prognostic with median PFS of 5.7 months for stage IV indolent and 3.5 months for stage IV aggressive patients [HR = 1.69; 90% confidence interval (CI), 1.27–2.24; P aggressive patients, F + P and F + P + A improved PFS versus fulvestrant alone (HR = 0.43; 90% CI, 0.25–0.71 and HR = 0.26; 90% CI, 0.14–0.49, respectively). No benefit was observed in stage IV indolent patients (interaction P = 0.0148 and P = 0.0033, respectively). Conclusions: Baseline CTC enumeration provides significant prognostic information in HR+/HER2− MBC. Stage IV aggressive patients derive greater benefit from F + P or F + P + A over fulvestrant alone, independent of clinical or ctDNA features. This highlights the potential of CTCs to guide treatment decision-making.
Year:
2025
Multivariable Cox regression in terms of PFS. CTCs enumeration was corrected for ESR1, PIK3CA, RB1 mutational status and clinically relevant features (i.e., visceral involvement, duration of prior CDK4/6 inhibitor, endocrine sensitivity, therapy between prior CDK4/6i and randomization).
Year:
2025
PACE Trial Schema. Total planned enrollment was 220 patients. Primary objective: superiority of fulvestrant+palbociclib vs fulvestrant alone (A). Secondary objective: superiority fulvestrant+palbociclib+avelumab vs fulvestrant alone (B).
Year:
2025
Collaborators (11)
Carolina Reduzzi
Assistant Professor
Weill Cornell Medicine
Priyanka Sharma
Associate Professor
University of Kansas Medical Center
Angela DeMichele
University of Pennsylvania
Cynthia X. Ma
Washington University in Saint Louis School of Medicine
Yara G Abdou
University of North Carolina at Chapel Hill
Sonya Reid
Vanderbilt University Medical Center
Rubina Qamar
Associate Professor
University of Wisconsin-Madison Carbone Cancer Center
Kathy Miller
Indiana University Bloomington
Erica Mayer
Dana-Farber Cancer Institute
Massimo Cristofanilli
Professor of Medicine
Weill Cornell Medicine
Reshma Mahtani
Chief of Breast Medical Oncology
Sylvester Comprehensive Cancer Center, University of Miami
Make your next move.
Prepare your application
Review drafts before you send them.